Jazz Pharmaceuticals-Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Core Viewpoint - Analysts expect Jazz Pharmaceuticals to report quarterly earnings of $5.79 per share, reflecting a year-over-year increase of 15.3%, with revenues projected at$ 1.06 billion, up 4.8% from the previous year [1] Revenue Estimates - Analysts estimate 'Revenues- Product sales, net' at $995.17 million, indicating a change of +2.9% year-over-year [4] - 'Total revenues- Neuroscience- Oxybate- Xywav' is projected to reach$ 393.28 million, suggesting a change of +16.7% year-over-year [4] - 'Total revenues- Neuroscience- Epidiolex/Epidyolex' is expected to be $264.59 million, reflecting a change of +10% from the prior year [5] - 'Total revenues- Neuroscience- Sativex' is estimated at$ 6.58 million, indicating a change of +28.2% year-over-year [5] - 'Total revenues- Neuroscience- Oxybate (Xywav & Xyrem)' is forecasted at $443.06 million, showing a change of -0.2% from the previous year [6] - 'Total revenues- Neuroscience- Total' is expected to reach$ 714.23 million, indicating a change of +3.6% year-over-year [6] - 'Total revenues- Oncology- Total' is projected at $276.22 million, reflecting a change of +0.9% from the prior year [6] - 'Total revenues- Oncology- Rylaze' is estimated at$ 99.81 million, indicating a change of -1.9% year-over-year [7] - 'Total revenues- Oncology- Defitelio/defibrotide' is expected to be $46.52 million, reflecting a change of -8.9% from the previous year [7] - 'Total revenues- Oncology- Vyxeos' is projected at$ 42.05 million, indicating a change of -10.4% year-over-year [8] - 'Total revenues- Oncology- Zepzelca' is expected to reach $91.31 million, reflecting a change of +23.4% from the prior year [8] - 'Total revenues- Other' is estimated at$ 3.84 million, indicating a change of -6.1% from the previous year [8] Stock Performance - Jazz shares have increased by +11.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by +2.6% [9]